Ameritas Investment Partners’s Palvella Therapeutics PVLA Stock Holding History

Ameritas Investment Partners’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$72.3K	Hold	580	–	–	﹤0.01%	1872
2025 Q4	$60.7K	Sell	580 -120	-17%	-$10.2K	﹤0.01%	1996
2025 Q3	$43.9K	Hold	700	–	–	﹤0.01%	2222
2025 Q2	$15.8K	Buy	+700	New	+$16.4K	﹤0.01%	2761
2021 Q2	–	Sell	-38	Closed	-$8K	–	3252
2021 Q1	$8K	Hold	38	–	–	﹤0.01%	2931
2020 Q4	$8K	Hold	38	–	–	﹤0.01%	2892
2020 Q3	$6K	Hold	38	–	–	﹤0.01%	2941
2020 Q2	$9K	Hold	38	–	–	﹤0.01%	2786
2020 Q1	$7K	Hold	38	–	–	﹤0.01%	2706
2019 Q4	$11K	Hold	38	–	–	﹤0.01%	2714
2019 Q3	$10K	Hold	38	–	–	﹤0.01%	2764
2019 Q2	$14K	Hold	38	–	–	﹤0.01%	2660
2019 Q1	$10K	Hold	38	–	–	﹤0.01%	2708
2018 Q4	$8K	Hold	38	–	–	﹤0.01%	2750
2018 Q3	$17K	Hold	38	–	–	﹤0.01%	2596
2018 Q2	$15K	Hold	38	–	–	﹤0.01%	2673
2018 Q1	$21K	Hold	38	–	–	﹤0.01%	2404
2017 Q4	$23K	Hold	38	–	–	﹤0.01%	2373
2017 Q3	$16K	Hold	38	–	–	﹤0.01%	2545
2017 Q2	$15K	Buy	+38	New	+$11.1K	﹤0.01%	2629

Other funds holding PVLA

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ameritas Investment Partners's PVLA Position: Q1 2026 in Review

Ameritas Investment Partners held its Palvella Therapeutics (PVLA) position steady in Q1 2026 at 580 shares worth $72.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1872.

Ameritas Investment Partners first reported a position in PVLA in Q2 2017 and has held it in 20 quarters since. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

Ameritas Investment Partners held 580 shares of Palvella Therapeutics worth $72.3K as of Q1 2026.
Ameritas Investment Partners left its Palvella Therapeutics share count unchanged in Q1 2026.
Palvella Therapeutics made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #1872 holding.
Ameritas Investment Partners first reported a position in Palvella Therapeutics in Q2 2017 and has held it in 20 quarters since.
180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.